If you can hold out for 2 years and if the phase 3 study provides good results you could have a winner in 3 years....well that's a lot of ifs and the only one calling the new glaucoma drug a winner is B&L...
B&L was formally shopped by Warburg Pincus to:
Allergan
Merck
Pfizer
Sanofi
Novartis
J&J
all who declined, given the ridiculous valuation Warburg was "imagining" B&L held. No further serious negotiation and/or discussions are ongoing. Instead, B&L has been focusing its efforts on going public. Unfortunately, the feedback they are getting indicates investors believe there is a general lack of near-term "growth drivers" (other than their new glaucoma drug, which will enter Phase 3 early 2013, and which looks like a winner), and thus B&L is seriously on the prowl for near term (2013-2015) revenue drivers.
B&L was formally shopped by Warburg Pincus to:
Allergan
Merck
Pfizer
Sanofi
Novartis
J&J
all who declined, given the ridiculous valuation Warburg was "imagining" B&L held. No further serious negotiation and/or discussions are ongoing. Instead, B&L has been focusing its efforts on going public. Unfortunately, the feedback they are getting indicates investors believe there is a general lack of near-term "growth drivers" (other than their new glaucoma drug, which will enter Phase 3 early 2013, and which looks like a winner), and thus B&L is seriously on the prowl for near term (2013-2015) revenue drivers.